Cyclacel Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
FITTERS Diversified Berhad has filed a Schedule 13G amendment, confirming zero beneficial ownership and no intent to influence control over Bio Green Med Solution, Inc.
Yap Kim Choy has filed a Schedule 13G amendment indicating zero beneficial ownership of Bio Green Med Solution, Inc. common stock as of June 30, 2026.
Individual investor Yap Kim Choy has filed a Schedule 13G reporting an 8.47% beneficial ownership stake in Bio Green Med Solution, Inc.
Ong Yee Lung filed Amendment No. 3 to Schedule 13G, disclosing zero beneficial ownership in Bio Green Med Solution, Inc.'s common stock as of December 31, 2025.
Kua Khai Loon has filed an amendment to Schedule 13G, reporting zero beneficial ownership in Bio Green Med Solution, Inc.'s common stock.
Ong Yee Lung has reported beneficial ownership of 11.79% of Bio Green Med Solution, Inc.'s common stock, primarily through warrants.
Yap Kim Choy has reported a 14.82% beneficial ownership stake in Bio Green Med Solution, Inc., primarily through common stock and warrants.
FITTERS Diversified Berhad has reported a 7.98% beneficial ownership stake in Bio Green Med Solution, Inc., holding 279,248 shares of common stock.
FITTERS Diversified Berhad has reported an increased beneficial ownership in Bio Green Med Solution, Inc., now holding 14.46% of its common stock.
Kua Khai Loon has disclosed a beneficial ownership of 16.35% in Bio Green Med Solution, Inc., comprising common stock and various warrants.
FITTERS Diversified Berhad has disclosed a significant 19.99% beneficial ownership stake in Bio Green Med Solution, Inc.
Ong Yee Lung has significantly increased beneficial ownership in Cyclacel Pharmaceuticals, Inc. to 20.76% through a combination of common stock and warrants.
Kua Khai Loon will beneficially own 20.76% of Cyclacel Pharmaceuticals, Inc. common stock and warrants, effective September 1, 2025.
Malaysian investor Yap Kim Choy has significantly increased beneficial ownership in Cyclacel Pharmaceuticals, Inc. to 20.76% through common stock and various series of warrants.
Yap Kim Choy has disclosed a 9.8% beneficial ownership stake in Cyclacel Pharmaceuticals, Inc., holding 218,000 shares.
Ong Yee Lung has reported a 9.8% beneficial ownership stake in Cyclacel Pharmaceuticals, Inc., holding 218,000 shares of common stock.
Malaysian investor Kua Khai Loon has disclosed a 9.8% beneficial ownership stake in Cyclacel Pharmaceuticals, Inc., holding 218,000 shares of common stock.
Armistice Capital, LLC and Steven Boyd have reported a complete divestment of their beneficial ownership in Cyclacel Pharmaceuticals, Inc., now holding 0% of common stock.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 9.20% of Cyclacel Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Maintain Significant Stake in Cyclacel Pharmaceuticals
Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.99% of Cyclacel Pharmaceuticals, Inc.'s common stock.